Zinc isotopic compositions of breast cancer tissue†

Fiona Larner,*ab Laura N. Woodley,c Sami Shousha,d Ashley Moyes,e Emma Humphreys-Williams,f Stanislav Strekopytov,f Alex N. Halliday,a Mark Rehkämperg and R. Charles Coombesg

An early diagnostic biomarker for breast cancer is essential to improve outcome. High precision isotopic analysis, originating in Earth sciences, can detect very small shifts in metal pathways. For the first time, the natural intrinsic Zn isotopic compositions of various tissues in breast cancer patients and controls were determined. Breast cancer tumours were found to have a significantly lighter Zn isotopic composition than the blood, serum and healthy breast tissue in both groups. The Zn isotopic lightness in tumours suggests that sulphur rich metallothionein dominates the isotopic selectivity of a breast tissue cell, rather than Zn-specific proteins. This reveals a possible mechanism of Zn delivery to Zn-sequestering vesicles by metallothionein, and is supported by a similar signature observed in the copper isotopic compositions of one breast cancer patient. This change in intrinsic isotopic compositions due to cancer has the potential to provide a novel early biomarker for breast cancer.

Introduction

Early diagnosis for breast cancer patients is critical to improve outcome, and a biomarker that could detect the disease early could be invaluable. High concentrations of zinc (Zn) have been noted in breast tissue for over a decade. The causative changes in Zn metabolism at the molecular level have remained elusive3–5 and traditional hospital-based measurements of metal metabolism are insufficiently sensitive to provide a diagnostic tool. New techniques for the high precision measurement of natural isotopic compositions are far more sensitive and have the potential to provide a novel early biomarker for breast cancer.

Zinc is an essential trace element required by the human body for more than 300 cellular processes7 but can be toxic in excess and therefore requires a high level of regulation. Zinc importer (Zip) and transporter (ZnT) proteins facilitate cellular zinc homeostasis3 and several proteins within these families appear disturbed in breast cancer cells. The anti-oxidant protein metallothionein (MT) is also known to have a significant role in cellular Zn metabolism, as well as for other essential metals such as copper. Levels of MT are poorly regulated in breast cancer.2 Zinc concentrations have been reported to be significantly higher in breast cancer tumours relative to healthy breast tissue, and lower in blood serum and erythrocytes of breast cancer patients compared to healthy controls.1,2,8,9 Increased levels of Zips are present in breast cancer cells leading to increased Zn uptake. Whilst some ZnT proteins promote Zn efflux by sequestering excess cellular zinc into vesicles for later use, extreme excess zinc triggers cell apoptosis in healthy cells.8 However the zinc transporter ZnT2 and MT are thought to be overexpressed in malignant breast cancer cells,21 which protects them from hyper accumulation of zinc and prevents tumour cell death.

Natural stable isotope fractionation is one of the most sensitive methods for exploring and quantifying environmental processes past and present. The development of multiple collector inductively coupled plasma mass spectrometry (MC-ICP-MS) has facilitated stable isotope measurements for a far broader range of elements than hitherto possible and provided important information about Earth’s formation, the evolution of life and mechanisms of climate change.10–12 Fractionation occurs when
the light- or heavy-mass isotope(s) of an element are transformed preferentially or more rapidly in a reaction, as a result of mass dependent differences in the energy budget of the process. This can happen, for example, due to changes in phase, ligand coordination and redox state, or transport processes, including biological uptake. The tightly controlled energy requirements of biological systems mean the related isotopic fractionation is typically significant, and facilitates a sensitive monitor of metabolic change. In particular, zinc isotopic fractionation could differ when a cellular process is altered because of a disease such as cancer; in principle it provides more insight than concentration changes alone. Here we report the results of a pilot investigation of Zn metabolism in breast cancer, by comparing how the isotopic composition in different reservoirs changes with malignancy.

Results & discussion

The Zn concentration and isotopic composition of blood and blood serum of healthy controls and breast cancer patients were determined, alongside a suite of 10 breast tissues, predominantly obtained from breast cancer patients (Fig. 1; Table 1). As observed in other investigations, the Zn concentration of tumours was found to be significantly higher than the average values for healthy breast tissue reported in literature and found in this study. The isotopic composition is expressed as the $^{66}\text{Zn}/^{64}\text{Zn}$ ratio. Variations in this composition due to isotopic fractionation are small so are reported as the deviation, $\delta^{66}\text{Zn}$, in parts per thousand ($\delta$, eqn (1)) relative to a widely available well-characterised source of zinc.

$$\delta^{66}\text{Zn} = \left(\frac{\left(\frac{^{66}\text{Zn}}{^{64}\text{Zn}}\right)_{\text{sample}}}{\left(\frac{^{66}\text{Zn}}{^{64}\text{Zn}}\right)_{\text{reference}}} - 1\right) \times 1000 \quad \text{(1)}$$

The samples of blood and of serum display limited isotopic variation ($\delta^{66}\text{Zn} = -0.1$ to $+0.3\%$). There is no systematic difference between samples from healthy controls or breast cancer patients. A haematoma sample from operation-induced trauma is more negative ($-0.2\%$) however. The most negative values ($-0.6$ to $-0.9\%$) are from breast cancer tissue. Healthy tissue from breast cancer patients and one healthy control show a Zn isotope composition lighter than blood and serum ($-0.3$ to $-0.5\%$), but not as isotopically light as breast cancer tissue. For one patient the healthy tissue was retrieved adjacent to the tumour tissue and demonstrates a Zn isotope fractionation of approximately $-0.5\%$ and an isotopic difference of around $-0.9\%$ between blood and tumour (Fig. 1). Therefore, isotopically lighter zinc appears to be sequestered during tumour formation.

Zinc metabolism in breast tissue is not fully understood, however, it is thought that it is imported into breast cells via Zips, buffered by MT and sequestered into intracellular vesicles by ZnTs, in addition to other interactions which incorporate Zn into functional roles (e.g. Zn-finger protein formation). Zinc isotopic fractionation can occur at any or all of these transformative steps but the net effect must be to produce an isotopically light zinc pool. Ab initio modelling and laboratory-based investigations of biological Zn interactions indicate that, because of the stronger bonds formed, heavier isotopes will preferentially bond to amino acids with harder ligands, such as nitrogen and oxygen, whereas lighter isotopes will be found with softer ligands such as sulfur. Both Zips and ZnTs are noted for their numerous histidine (and therefore nitrogen rich) residues. Therefore, they are unlikely candidates for developing an isotopically light composition. Metallothionein (MT) in contrast is S rich and capable of binding up to seven Zn ions with its 20 cysteine residues. Metallothionein, rather than a zinc-specific protein, is therefore most probably responsible for the relatively light Zn isotope composition of healthy tissue relative to blood, and of tumour tissue relative to its healthy counterpart. The data indicate that the up-regulation of Zips, ZnTs and MT in cancer cells magnifies the same isotopic processes occurring in healthy cells, whereby the selectivity of the MT overrides any heavy isotopic preference induced by the Zn specific proteins.

This hypothesis is supported by the behaviour of copper (Cu) isotopes in the same tissues (Fig. 2), which we have analysed in a small number of samples (Table 1). Copper is not subject to cell processes governed by Zn-specific proteins, however the isotopic composition of Cu in the tumour relative to the adjacent healthy tissue is isotopically lighter by $-0.4\%$ (Fig. 2). Copper management is governed partly by copper-specific proteins, (e.g. ATP7A, B, CTR1, ATOX1) as well as metallothionein. There have been no reported up-regulation in Cu-transporter proteins in breast cancer cells, therefore the observed isotopic shift from healthy tissue to tumour is most likely caused by binding of Cu to increased amounts of MT present in the cell. This indicates that the magnitude of isotopic fractionation of different transition metals by this protein is similar.

To preserve mass balance in the system, the sequestration of isotopically light zinc into breast cancer cells requires an isotopically heavy Zn pool to be present in the body as the remnant of the original zinc source. Identification of this pool could provide a new method of diagnosis. The difference in
### Table 1  Summary of patient information, zinc and copper isotope compositions and concentration data for individuals and standard materials

<table>
<thead>
<tr>
<th>Sample</th>
<th>Gender</th>
<th>Grade (% tumour cellularity)</th>
<th>Type</th>
<th>[Zn] µM</th>
<th>$\delta^{66}$Zn&lt;sub&gt;IRMM-3702&lt;/sub&gt; (%)</th>
<th>$\delta^{65}$Cu&lt;sub&gt;ERM-AE653&lt;/sub&gt; (%)</th>
<th>2s (%)</th>
<th>n (m)</th>
<th>[Cu] µM</th>
<th>$\delta^{65}$Cu&lt;sub&gt;ERM-AE65&lt;/sub&gt; (%)</th>
<th>2s (%)</th>
<th>n (m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference materials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>London Zn</td>
<td></td>
<td></td>
<td>Pure solution</td>
<td>—</td>
<td>−0.19</td>
<td>+0.10</td>
<td>±0.10</td>
<td>60</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRMM 3702 Zn</td>
<td></td>
<td></td>
<td>Pure solution</td>
<td>—</td>
<td>0.00</td>
<td>+0.10</td>
<td>±0.10</td>
<td>6</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romil Cu</td>
<td></td>
<td></td>
<td>Pure solution</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCR-639</td>
<td></td>
<td></td>
<td>Serum</td>
<td>40.9</td>
<td>−3.06</td>
<td>±0.20</td>
<td>8</td>
<td>5</td>
<td>16.0</td>
<td>−0.53</td>
<td>±0.06</td>
<td>1</td>
</tr>
<tr>
<td>Controls</td>
<td></td>
<td></td>
<td>Blood</td>
<td>101</td>
<td>0.07</td>
<td>±0.15</td>
<td>1</td>
<td>14.4</td>
<td>−0.08</td>
<td>±0.06</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Serum</td>
<td>11.0</td>
<td>0.15</td>
<td>±0.11</td>
<td>2(2)</td>
<td>12.8</td>
<td>−0.57</td>
<td>±0.16</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn002 HC F</td>
<td></td>
<td></td>
<td>Blood</td>
<td>84.9</td>
<td>0.09</td>
<td>±0.10</td>
<td>2(2)</td>
<td>10.8</td>
<td>0.78</td>
<td>±0.16</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn003 HC F</td>
<td></td>
<td></td>
<td>Blood</td>
<td>90.8</td>
<td>0.15</td>
<td>±0.10</td>
<td>2(2)</td>
<td>12.3</td>
<td>0.93</td>
<td>±0.16</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn004 HC F</td>
<td></td>
<td></td>
<td>Serum</td>
<td>14.6</td>
<td>0.28</td>
<td>±0.10</td>
<td>1</td>
<td>15.8</td>
<td>−0.43</td>
<td>±0.16</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn007 HC F</td>
<td></td>
<td></td>
<td>Blood</td>
<td>93.3</td>
<td>0.07</td>
<td>±0.10</td>
<td>2(2)</td>
<td>12.8</td>
<td>1.03</td>
<td>±0.06</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn007 HC M</td>
<td></td>
<td></td>
<td>Blood</td>
<td>96.1</td>
<td>0.14</td>
<td>±0.09</td>
<td>1</td>
<td>13.0</td>
<td>0.11</td>
<td>±0.11</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn008 HC M</td>
<td></td>
<td></td>
<td>Blood</td>
<td>76.9</td>
<td>0.11</td>
<td>±0.12</td>
<td>1</td>
<td>11.5</td>
<td>0.23</td>
<td>±0.11</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn014 HC F</td>
<td></td>
<td></td>
<td>Healthy tissue</td>
<td>98.8</td>
<td>−0.31</td>
<td>±0.06</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td></td>
<td></td>
<td>Blood</td>
<td>58.1</td>
<td>0.20</td>
<td>±0.09</td>
<td>1</td>
<td>16.0</td>
<td>0.25</td>
<td>±0.11</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn002 F 2</td>
<td></td>
<td></td>
<td>Serum</td>
<td>61.1</td>
<td>0.13</td>
<td>±0.10</td>
<td>3(3)</td>
<td>10.4</td>
<td>0.74</td>
<td>±0.16</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn003 M 2 (80)</td>
<td></td>
<td></td>
<td>Serum</td>
<td>13.9</td>
<td>0.22</td>
<td>±0.10</td>
<td>2(2)</td>
<td>15.3</td>
<td>−0.60</td>
<td>±0.16</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn005 M 3</td>
<td></td>
<td></td>
<td>Serum</td>
<td>70.8</td>
<td>0.01</td>
<td>±0.10</td>
<td>2(2)</td>
<td>11.1</td>
<td>0.08</td>
<td>±0.06</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn006 M 1 (90)</td>
<td></td>
<td></td>
<td>Serum</td>
<td>13.4</td>
<td>−0.04</td>
<td>±0.10</td>
<td>2(2)</td>
<td>11.9</td>
<td>−0.96</td>
<td>±0.12</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn009 F 3 (&gt; 90)</td>
<td></td>
<td></td>
<td>Tumour</td>
<td>64.3</td>
<td>−0.77</td>
<td>±0.08</td>
<td>2(2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zn010 F 2 (50)</td>
<td></td>
<td></td>
<td>Tumour</td>
<td>95.8</td>
<td>0.05</td>
<td>±0.10</td>
<td>1</td>
<td>14.6</td>
<td>0.07</td>
<td>±0.06</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn011 F 2 (90)</td>
<td></td>
<td></td>
<td>Tumour</td>
<td>78.5</td>
<td>0.09</td>
<td>±0.14</td>
<td>1</td>
<td>12.6</td>
<td>0.62</td>
<td>±0.06</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn012 F 2</td>
<td></td>
<td></td>
<td>Tumour</td>
<td>13.1</td>
<td>0.03</td>
<td>±0.10</td>
<td>2(2)</td>
<td>14.0</td>
<td>−0.45</td>
<td>±0.06</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Zn013 F 2</td>
<td></td>
<td></td>
<td>Healthy tissue</td>
<td>156</td>
<td>−0.90</td>
<td>±0.06</td>
<td>1(2)</td>
<td>10.2</td>
<td>0.48</td>
<td>±0.06</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

a For isotope compositions, $n =$ number of full procedural separations, $m =$ number of analytical sessions on MC-ICP-MS. Italicized concentrations determined from MC-ICP-MS data.

*For* isotope compositions, *n* = number of full procedural separations, *m* = number of analytical sessions on MC-ICP-MS. Italicized concentrations determined from MC-ICP-MS data.

iso*te composition of Zn caused by the tumour is not detectable in the blood or serum of cancer patients relative to healthy controls (Fig. 1). The $\delta^{66}$Zn value of blood has been shown to vary by ±0.2‰ due to diet, therefore the normalization of each individual's serum Zn isotope composition to the blood composition can be used to remove scatter introduced by dietary influence. This, however, does not increase resolution between the two groups, and confirms that the simple measurement of these easily accessible sample types cannot be used to identify the diagnostic heavy Zn isotope pool if analysed in bulk form.

The mixing of two reservoirs can change the isotopic composition of the resultant pool to varying degrees and is represented by the haemotama sample (blood pool with healthy tissue cells) analysed (Fig. 1). This sample has a Zn isotopic composition between that of blood and the healthy tissue samples, representing the mixing of the two pools in this sample, whereby the contribution of the healthy tissue cells is large enough to perturb the intrinsic composition of the blood. Using mixing calculations (see ESI†) and the average zinc isotope values and concentrations of the blood and tumours measured here, it can be shown that the lack of signal in the blood from tumour growth is to be expected. The background zinc pool in the blood, typically ~5 L of 100 µM Zn, is too large and acts as a buffer to the small reservoir of isotopically heavy excreted zinc originating from the tumour; for example, growth of a 1 g tumour would perturb the Zn isotope composition of blood ($\delta^{66}$Zn) by < 0.0005‰.

Although bulk blood does not reveal an isotopic effect it would be important to be able to identify and isolate a more discrete isotopically heavy pool of Zn that is residual to the light tumour-sequestered Zn. It could provide an important early biomarker for the disease. The mechanism resulting in the expulsion of isotopically heavy Zn from the tumour cells is key to finding the appropriate compartment containing the biomarker and, for example, could be in white blood cells or a specific protein size fraction from blood. The mass balance of
Changes in zinc metabolism on tumour formation in breast cancer are reflected in the change of natural intrinsic zinc isotopic composition of breast tissue. Whilst the causes are not certain, this observation implicates the potential use of high precision isotopic analysis to develop a new, early biomarker for breast cancer.

### Conclusion

Mechanistic changes in zinc metabolism on tumour formation in breast cancer and shed light on specific Zn transfer mechanisms but also indicate the progression of the disease.

### Experimental

#### Sample collection

This study was approved by the Tissue Management Committee of the Imperial College NHS Healthcare Tissue Bank. Informed patient consent was obtained before the collection of samples. Sample collection was performed at Charing Cross Hospital, Imperial College NHS Trust, London UK. Samples were collected in clean Teflon vials from breast cancer patients (blood, serum, tumour, healthy tissue, haematoma) and age matched controls (blood, serum). Tumour and haematoma samples were taken using precleaned ceramic knives, with the exception of three previously collected tumor samples supplied directly from the tissue bank in plastic vials.

#### Sample preparation

Samples were prepared for Zn and Cu isotopic composition and concentration analysis in Class 10 laminar flow hoods either in the MAGIC Clean Room Laboratory, Imperial College London or at the Clean Laboratory Suite at the University of Oxford. Quartz distilled acids diluted with 18 MΩ cm H₂O (Millipore) if necessary were used throughout for sample preparation. Samples (0.25–0.5 ml or <0.5 g) were microwave digested in a 3 + 2 mixture of 15 M HNO₃ + 30% H₂O₂ (vol/vol) ramping over 90 min to 210°C, 250 psi.

#### Concentration and isotopic analysis

Zinc and copper concentrations were determined by ICP-AES and ICP-MS at the Natural History Museum, London (Table 1). The Zn concentrations were used to allow accurate double spiking prior to Zn isolation from the sample matrix via anion exchange chromatography. Isotope analyses were performed using the Nu Instruments Nu Plasma HR MC-ICP-MS at the appropriate resolution mode (Cu: low, Zn: medium) with either an Aridus (Cetac, ICL) or a DSN (Nu Instruments, Oxford) desolvating sample introduction system. Isotope measurements were performed as previously described. A reference solution was measured at least twice either side of sample analyses to monitor and allow accurate correction of changes in instrumental mass bias, as described previously. The data retrieved from the MC-ICP-MS measurements were used to calculate the difference in isotope composition (δ⁶⁵Zn or δ⁶⁵Cu).
of a sample (sam) relative to the average of the bracketing standard solutions (std; equation 1), Cu by exponential normalization with nickel²⁴ and Zn by double spike deconvolution.²³ Isotopic values are reported relative to the well-characterised materials IRMM-3702 (Zn) and ERM-AE633 (Cu).²⁷ The Zn and Cu blank contribution were monitored to ensure results were not influenced by background levels and was typically <1% of the total sample Zn or Cu respectively. The reproducibility of the methods were monitored by (i) repeat measurements of an in house standard alongside samples, (ii) the processing and measurement of the same samples through the whole method twice, and (iii) the measurement of a matrix matched standard material, BCR-639 Human serum, with multiple batches of samples (Table 1). The external reproducibility of the in house standard is ±0.10‰ (2SD) and the vast majority of the samples are within this uncertainty, and all are within the reproducibility of the matrix matched standard.

Acknowledgements

Tissue samples were provided by the Imperial College Healthcare NHS Trust Tissue Bank. Other investigators may have received samples from these same tissues. This study was supported by an ERC Advanced Fellowship to A.N.H., Pfizer (IES) grant PX0602_WSCC to R.C.C. and Impact Acceleration Awards from STFC and EPSRC to M.R and F.L. Author contributions: L.N.W. and A.M. coordinated patient consent and sample collection; S.Sh. provided tissue samples and histopathological data; E.H-W. and S.St. performed concentration analyses; F.L., R.C.C. and M.R. designed the study; A.N.H. was involved in study design and data analysis; A.N.H. and M.R. were involved in manuscript preparation; F.L. digested, separated, performed MC-ICP-MS analyses, analysed the data and wrote the paper. All authors discussed the findings and commented on the manuscript.

References

23 T. Arnold, M. Schönbachler, M. Rehkämper, S. Dong, F.-J. Zhao, G. J. D. Kirk, B. J. Coles and D. J. Weiss, Measurement


